Lactoferrin (17-41) (acetate)
(Synonyms: Lactoferricin B acetate; Lfcin B acetate) 目录号 : GC60221
Lactoferrin 17-41 (Lactoferricin B) acetate 对应于牛乳铁蛋白的残基 17-41，对革兰氏阳性和革兰氏阴性细菌、病毒、原生动物和真菌等多种微生物具有抗菌活性。Lactoferrin 17-41 acetate 具有抗肿瘤活性。
Cas No.:2828433-30-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lactoferrin 17-41 (Lactoferricin B) acetate, a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 acetate has antitumor activities[1][2].
Lactoferrin 17-41 (Lactoferricin B) acetate has an MIC of 30 μg/ml against E. coli ATCC 25922[1].Lactoferrin 17-41 acetate significantly stimulates apoptosis of HT-29 cells and displays cytotoxic activity on HT-29 cells[2].Lactoferrin 17-41 acetate variously regulats transcription of genes involved in the p53 signaling pathway, such as PMAIP-1, TP5313, and SFN[2].Lactoferrin 17-41 acetate can bind LPS from Gram-negative bacteria and that it can inhibit LPS induced cytokine response in human monocytic cells[1][3]. Cell Viability Assay[1] Cell Line: HT-29 cells
[1]. Samuelsen Ø, et al. Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol. 2004 Jun 1;41(2):141-8. [2]. Jiang R, et al. Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells(HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017 Feb;95(1):99-109. [3]. Latorre D, et al. Reciprocal interactions between lactoferrin and bacterial endotoxins and their role in the regulation of the immune response. Toxins (Basel). 2010;2(1):54‐68.
| Cas No. | 2828433-30-1 | SDF | |
| 别名 | Lactoferricin B acetate; Lfcin B acetate | ||
| 分子式 | C143H226N46O33S3 | 分子量 | 3183.82 |
| 溶解度 | DMSO : 20 mg/mL (6.28 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3141 mL | 1.5704 mL | 3.1409 mL |
| 5 mM | 0.0628 mL | 0.3141 mL | 0.6282 mL |
| 10 mM | 0.0314 mL | 0.157 mL | 0.3141 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet